PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10505693-7	1999	Compared to placebo, urinary AQP-2 excretion decreased significantly and in all groups in a dose-dependent manner during VPA-985 administration.	lixivaptan	121-128	aquaporin 2	Homo sapiens	29-34	
31888044-0	2019	Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells.	lixivaptan	0-10	aquaporin 2	Homo sapiens	71-82	
31888044-7	2019	In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256.	lixivaptan	53-63	aquaporin 2	Homo sapiens	143-147	
31888044-9	2019	These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention.	lixivaptan	118-128	aquaporin 2	Homo sapiens	77-81